FLORENCE FAUVELLE

I am specialized in Nuclear Magnetic Resonance (NMR) spectroscopy of small molecules, mainly in biomedical research field.

► Metabolomics to investigate metabolism and to improve diagnosis

• HRMAS NMR (High Resolution Magic Angle Spinning) for unprocessed sample analysis,
• High resolution NMR  (biofluids e.g. serum, cerebrospinal fluid, fecal water...)
• Multivariate statistics : PCA, OPLS-DA..

► NMR study of interactions

• Intercalation of heterocycles with synthetic oligonucleotides
• Complexation of small molecules with different  cyclodextrins, using multi-nuclei NMR and mass spectrometry (thesis)
• Drugs-membranes interactions (phospholipidic Liposomes) using  ¹H, ³¹P, ²H NMR.

► Quantification of NMR signals

• Semi-automatic quantification of HRMAS NMR brain tissus, collaboration to the development of  jMRUI/QUEST algorithm (collaboration D. Graveron, Université Lyon1, La Doua, Villeurbanne).

► Master 2, UFR Chimie biologie, UGA

• Master 2 “High throughput in biology”, “High throughput NMR: metabolomics” 3h/an depuis 2015.
• Master 2 “Cancer disease: experimental and therapeutic approaches”, “Metabolomics in cancer research” 3h/an 2015-2023.

► AI4OneHealth, UGA

• AI4 omics, “NMR-based metabolomics”, 2021-2023.

► DUT Mesures Physiques, UGA

• Initiation à la RMN, 8h/an, 1999 à 2009,
• Sectroscopie, 45h/an, 1999 à 2001.M

Formation:

► Expérimentation animale pour les cadres (niveau I), Université Grenoble Alpes (juin 2011).

► Habilitation à Diriger les Recherches (HDR) diplôme de l’Université Grenoble Alpes (03 décembre 2010) intitulé « Application de la RMN HRMAS à l’étude du métabolisme et la métabolomique ».

► Doctorat de l'Université Grenoble Alpes, Grenoble (29 avril 1999) mention très honorable avec félicitations du jury, spécialité Génie Biologique et Médical. " Décontamination biologique des cations toxiques : la voie des cyclodextrines"

Positions

► Grenoble Institut des neurosciences depuis juillet 2013, unité Neuroimagerie fonctionnelle et perfusion cérébrale,

Plateforme IRMaGe, responsable métabolomique depuis 2013.

► Centre de Recherche du Service de Santé des Armées (CRSSA), Avril 1990- juin 2013, Unité de Biophysique cellulaire et moléculaire, laboratoire RMN.

Responsable du parc RMN du CRSSA (2 spectromètres RMN Bruker), mise à niveau technologique, et gestion des budgets du laboratoire de RMN

Mallet D., Goutaudier R., Dufourd T., Barbier EL., Carnicella S., Colca JR., Fauvelle F.* Boulet S.* (* Co-senior authors). Re-routing metabolism by the mitochondrial pyruvate carrier inhibitor MSDC-0160 attenuates neurodegeneration in a rat model of Parkinson’s disease, Molecular Neurobiology, DOI: 10.1007/s12035-022-02962-9, 2022.

Mallet D., Dufourd T., Decourt M., Carcenac C., Bossù P., Verlin L., Fernagut PO., Benoit-Marand M., Spalletta G., Barbier EL., Carnicella S., Sgambato V., Fauvelle F.* Boulet S.* (* Co-senior authors). A metabolic biomarker predict Parkinson’s disease at early stages in patients and in animal models, Journal of Clinical Investigations DOI: 10.1172/JCI146400, 2022.

Guillon A. Diakite D., Cezard A., Baranek T., Bourgeais J., Picou F., Hervé V., Carballido J., Nadal Desbarats L., Auvet A., Dingli  F., Turtoi A., Le Gouellec A., Fauvelle F., Crépin T., Hiemstra P.S., Paget C., Loew D., Herault O., Naffakh N., Le Goffic R. and Si-Tahar M. Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein, EMBO DOI: 10.15252/embj.2021108306, 2022.

Clement A., Doyen M., Fauvelle F., Hossu G., Chen B., Barbery-Heyob M., Hirtz A., Lamiral Z., Pouget C., Gauchotte G., Karcher G., Beaumont M., Verger A., Lemasson B. In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1-mutation expression by multiparametric magnetic resonance imaging and spectroscopy in rat model with orthotopically-grafted human-derived glioblastoma cell lines. NMR biomed doi.org/10.1002/nbm.4490, 2021.

Lo Presti C., Fauvelle F., Jacob MC., Mondet J., Mossuz P. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker, Blood Advances doi.org/10.1182/bloodadvances.2020002981, 2021.

Hamelin S., Stupar V., Maziere L., Guo J., Labriji W., Liu C., Bretagnolle L., Parrot S., Barbier EL., Depaulis A., Fauvelle F. In vivo GABA increase as a biomarker of the epileptogenic zone : an unbiased metabolomics approach, Epilepsia doi.org/10.1111/epi.16768, 2020.

Vial J., Huchedé P., Fagault S., Basset F., Rossi M., Geoffray J., Soldati H., Bisaccia J., Elsensohn M.H., Creveaux M., Neves D., Blay J.Y., Fauvelle F., Bouquet F., Streichenberger N., Corradini N., Bergeron C., Maucort-boulch D., Castets P., CARRE M., Weber K., CASTETS, M. Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways. Cell Death Discovery doi.org/10.1038/s41420-020-00302-1, 2020.

Lo presti C., Fauvelle F., Mondet J., Mossuz P. The differential activation of metabolic pathways in leukemic cells depending on their genotype and micro‑environmental stress. Metabolomics, doi.org/10.1007/s11306-020-1633-z, 2020

Sinniger V., Pellissier S., Fauvelle F., Trocmé C., Hoffmann D., Vercueil L., Cracowski J.L., David O. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterology & Motility., doi.org/10.1111/nmo, 2020